key: cord-0901879-hak8ri9i authors: Maggi, Enrico; Azzarone, Bruno Giuseppe; Canonica, Giorgio Walter; Moretta, Lorenzo title: What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders date: 2021-10-12 journal: Allergy DOI: 10.1111/all.15112 sha: b2648708de489f1fc1c9e3bb4f12e00c7ca50890 doc_id: 901879 cord_uid: hak8ri9i The coronavirus disease 2019 (COVID‐19) pandemic started in March 2020 and caused over 5 million confirmed deaths worldwide as far August 2021. We have been recently overwhelmed by a wide literature on how the immune system recognizes severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and contributes to COVID‐19 pathogenesis. Although originally considered a respiratory viral disease, COVID‐19 is now recognized as a far more complex, multi‐organ‐, immuno‐mediated‐, and mostly heterogeneous disorder. Though efficient innate and adaptive immunity may control infection, when the patient fails to mount an adequate immune response at the start, or in advanced disease, a high innate‐induced inflammation can lead to different clinical outcomes through heterogeneous compensatory mechanisms. The variability of viral load and persistence, the genetic alterations of virus‐driven receptors/signaling pathways and the plasticity of innate and adaptive responses may all account for the extreme heterogeneity of pathogenesis and clinical patterns. As recently applied to some inflammatory disorders as asthma, rhinosinusitis with polyposis, and atopic dermatitis, herein we suggest defining different endo‐types and the related phenotypes along COVID‐19. Patients should be stratified for evolving symptoms and tightly monitored for surrogate biomarkers of innate and adaptive immunity. This would allow to preventively identify each endo‐type (and its related phenotype) and to treat patients precisely with agents targeting pathogenic mechanisms. we have been overwhelmed by an enormous number of reports on SARS-CoV-2 infection and COVID-19 pathogenesis. Although originally defined as a respiratory viral infection, COVID-19 is now clearly recognized as a far more complex, multistep, multi-organ, immunomediated, and mostly heterogeneous disease. The angiotensin-converting enzyme-2 (ACE2) is one of the SARS-CoV2 receptors and in ACE2-bearing cells (as monocytes/ macrophages and epithelial cells), the virus triggers pattern recognition receptors as toll-like receptors (TLRs) and cytosolic sensors. Their signaling essentially follows three pathways leading to the type I/III interferon (IFN) secretion, the expression of costimulatory molecules for T-cell activation, and production of pro-inflammatory cytokines and chemokines. 1 This contributes to the activation of innate and adaptive immune responses, in particular of NK cells and virus-specific cytotoxic CD8+ T cells. In mild/moderate COVID-19 patients, such CD8+T cells are clonally expanded with a high amplification rate and express tissue-residence molecules (CXCR-6, and XCL1). 2 In these patients, increased virus-specific T follicular helper (Tfh) cells cooperate with B cells to mount a protective humoral response. It starts 1-2 weeks from infection, even though in some asymptomatic/mild cases antibodies (Abs) increase much later. In some asymptomatic people, the virus-specific T cells and Abs are totally missing. 3 The virus-specific IgA usually correlates with the IgG response, but the IgA monomers are twofold less potent than IgG, while the IgA dimers, associated with respiratory mucosa, are 7.5 times more potent than IgG. Thus, dimeric IgA response may be particularly valuable for protection against SARS-CoV-2. 4 In recovered individuals circulating resting memory B (mB), cells recognizing S1 proteins are consistently detectable. The anti-S1 Abs decline rapidly in 4 months from the infection and remain detectable for at least 11 months, correlating with the number of long-lived S1-specific plasma cells in bone marrow. 5 Both innate and adaptive immunity control the viral infection and determine clinical recovery in the majority of infected people; however, the virus negatively impacts on the IFN signaling pathway in infected cells leading to an impaired viral control. This triggers a persistent innate response preventing adequate adaptive immune responses. These patients show reduced circulating CD4+ and CD8+ T cells expressing inflammatory genes, membrane activation markers, and altered function. 6, 7 In severe/critical infections, CD8+ T cells do not display a clonal expansion, are phenotypically heterogeneous, and exhibit exhaustion phenotype. 2 Of note, the neutralizing anti-virus (S1 and receptor binding domain -RBD) Abs are usually higher in critical as compared to the non-critical patients. 8, 9 Such prevalent innate-induced inflammation can lead to a cytokine storm-like disorder and interstitial pneumonia, contributing (together with direct action of the virus) to a diffuse organ involvement and failure. COVID-19 pneumonia shows immunological features different from other common respiratory viral infections. For instance, it associates with higher levels of pro-inflammatory cytokines, procoagulative state, NLRP3 inflammasome (NI) activation, and altered fatty acids profiles as compared to H1N1 infection. 10 More importantly, the dysfunction of NK and T cells and the hyperactivation of macrophages and neutrophils in COVID-19 respiratory infection are absent in H1N1 pneumonia. 11 Lastly, eosinopenia in COVID-19 is more pronounced than in other viral infections, including influenza. 12 Although eosinophils can promote broad-spectrum antiviral activity or serve to regulate immunity at sites of viral infection, it is at present unclear whether eosinopenia in COVID-19 is consequent to their massive homing to tissues. The cytokine excess of severe COVID-19 could be also responsible for eosinophils margination or apoptosis. 13, 14 Notably, eosinophils of COVID-19 patients overexpress the programmed death receptor ligand-1 which is induced by IFNγ hyper-production and correlates with disease severity. 15, 16 At present, a major unanswered question is, why the viral immune evasion may predominate on the host immunity leading to hyper activation of innate response only in a proportion of patients. Even though many hypotheses have been proposed, the causes inducing variable responses of the immune system along such a multistep disease are only partially known. 17, 18 We will discuss such pathogenic hypotheses, taking into account that each mechanism is not mutually exclusive and underscoring the high heterogeneity of immune responses and clinical patterns. The virus exploits mechanisms inhibiting components of the IFN signaling pathway in infected cells as plasmacytoid dendritic cells (pDCs). The low IFN detected in COVID-19 patients suggests a potential defect in antiviral defenses, which is negatively associated with disease severity. 19 While SARS-CoV-2 is highly sensitive to IFN, it can interfere with downstream signaling at several levels, or inhibit IFN-stimulated gene products. 20 Remarkably, ACE2 expression on epithelial cells is upregulated by IFN itself; thus, the virus can even utilize the residual anti-viral molecule (IFN) for further entry into these cells. 21 In addition, pDCs (the main source of IFN) are decreased in COVID-19 due to recruitment into tissues and apoptosis. 22 When the innate response lasts too long, SARS-CoV-2 further replicates and compromises the adaptive immune responses. 18 The reduced pDCs can be responsible for the impaired presentation of viral epitopes to T cells and for natural killer (NK) cells dysfunction. 23 Impaired NK cells can also be due to: (i) Over-production of cytokines (mainly IL-6) by infected cells, which induces NK exhaustion, 24 (ii) spike subunit 1 (S1) which, through GATA3 activation, mediates HLA-E expression and CCL26 secretion by lung epithelium. CCL26 selectively favors NK cells homing into the lung; however, the interaction of HLA-E with NKG2A-CD94 inhibitory receptor leads to NK cell inhibition/exhaustion, 25, 26 (iii) KLRC2 gene (encoding the activating receptor NKG2C) deletion or HLA-E*0101/0103 variants (poorly recognized by NKG2C) with consequent reduction/absence of NKG2C+ "memory" NK cells 27 ; (iv) impaired release into bloodstream and tissues of "inflammatory" (CD34 + DNAM1 bright CXCR4+) precursors from the bone marrow, rapidly differentiating into mature NK progenies. 28, 29 The factors delaying adaptive immunity are mostly related to early impairment of innate responses. The increasing number of Myeloid-Derived Suppressive Cells (MDSC) and of suppressive factors as endogenous corticosteroids, TGFβ and IL-10, may condition the timing of the adaptive cellular response. High serum IL-10 in COVID-19 (mainly in critical/non-survivors) mimics systemic sepsis. 18 [30] [31] [32] This agrees with reports in which innate cytokine/chemokine signatures of immunopathology 22 have been associated with end-stage COVID-19 disease. 33 The lack of temporal coordination between innate and adaptive responses allows the persistence of a sustained viral load, which can trigger subsequent waves of inflammation worsening clinical outcomes. 23 SARS-CoV-2-specific T cells have been detected in about 50% of unexposed individuals, suggesting T cell cross-reactivity between SARS-CoV-2 and common cold coronaviruses (CCC), which affect >75% of the general population. 34 Pre-existing memory T cells could favor a faster and stronger adaptive immune response upon exposure to SARS-CoV-2, limiting disease severity. Such a secondary-like response could associate with a faster increase in memory Tfh cells, activation of B cells, and rapid humoral response. If polymerized, some viral antigens can also directly trigger mB cell proliferation leading to short-term antibody production. 18 This looks like what happens in recovered patients, where a robust virus-specific T cell response is maintained, preventing reinfection. 35 The pre-existing memory T cells might, however, be harmful, eliciting an antibody-mediated disease enhancement mechanism. 36 Sustained response of pre-existing T cells may be detrimental if associated with a dysfunction of naive-and induced-T regulatory (Treg) cells. 37 Since Treg cells limit antiviral responses and tissue immunopathology, 38 their reduction may favor a vigorous amplification of any (specific or non-specific) T cell response including autoreactive T cells triggering autoimmunity. The direct interaction of CD147 (an inducer of metalloproteases mainly expressed on early activated memory Treg cells) and S1 protein has been suggested to be responsible for Treg cell dysfunction observed in severe COVID-19. 23, 32, 38, 39 Regarding pre-existing humoral response, it was reported that, in naïve and, mostly, in recovered and vaccinated (mRNA) individuals, anti-S1-secreting plasmablasts peaked one week after the second challenge and then disappeared three weeks later 40 ; notably, B cells recognizing also S proteins of CCC strains have been observed in these subjects. 41 Furthermore, Abs produced by germinal center (GC) B cells of lymph nodes from 8-month-vaccinated people, recognized not only the S1/RBD and N domain of SARS-CoV2 but also S1 epitopes shared with some CCC strains. As described in seasonal influenza virus vaccination, these cross-reactive B cells displayed higher levels of somatic hypermutation suggesting a strong mB cell origin. 40, 42, 43 The similarity between severe COVID-19 and sepsis suggests that 45 The analysis of TCR repertoire from patients with severe disease indicates a TCR skewing with extensive junctional diversity, enrichment of Vβ genes, and increased J diversity, all consistent with SAtgs-induced activation. 46 Since SAtgs bind the monomorphic sequences of TCR and MHC class II, they may polyclonally activate a proportion of T and B cells and contribute to their dysfunction. 44 Notably, the pathogenic role of SAtg of S1 needs to be further evaluated and the described mechanism remains largely speculative. It is likely that the polyclonal T and B cell activation induced by SARS-CoV2 SAtg sequences could be crucial in the presence of some additional mechanisms as an early impairment of Treg cells or superinfection with other pathogens displaying SAtgs. Notably, no data are available on the presence of SAtgs of S1 proteins produced by COVID-19 vaccines. Furthermore, by analyzing the specificities toward more than 2500 extracellular and secreted proteins, it was found that severe COVID-19 patients exhibited a dramatic increase in auto-Abs compared to uninfected people. They recognize cytokines, chemokines, complement -C'-components, and cell surface proteins; thus, modulating immune responses and viral load control in a very heterogeneous manner. 55 Apparently, in odds with the ability of SARS-CoV2 to elicit autoimmunity, many reports indicate that AAD patients, clinically stabilized with immunosuppressive drugs, display, if infected with SARS-CoV-2, similar morbidity rates of the general population. 56 It has been suggested that such treatment regimens likely allow to dampen some pathogenic mechanism of infection. This applies also to allergic patients infected by SARS-CoV2, who display similar morbidity to the general population, likely due to some chronic therapeutic regimen. 57 Budesonide (an inhaled corticosteroid -ICS), largely employed in asthma, if administered at the initial phase of SARS-CoV2 infection, has been shown to markedly reduce viral load and persistence, duration, and severity of symptoms and timing of recovery in recently infected non-asthmatic patients. 58 It has been shown that ICS locally impair ACE2 expression on respiratory mucosa through the inhibition of IFN. 59, 60 However, two retrospective studies on large cohorts of patients curb enthusiasm on the regular ICS use in protecting asthmatic patients against COVID-19 infection. 61, 62 Oral corticosteroids (OCS) also reduce ACE2 expression and virus entry, but they heavily blunt systemic immunity with the risk of increases in viral load if administered early: OCS are indicated to reduce inflammation and mortality risk only in severe patients. 63 The control of SARS-CoV2 infection in respiratory allergy may also be due to anti-histamine drugs. The rationale for their use is that the virus directly activates mast cells (expressing ACE2) secreting histamine in COVID-19 pneumonia and that several anti-histamines prevent SARS-CoV2 entry in in vitro models. 64, 65 In addition, patients treated with these drugs are more resistant to SARS-CoV2, and cetirizine and famotidine alleviate pulmonary symptoms in COVID- 19. 66 These data, confirming the protective effects toward SARS-CoV2 infection of several anti-inflammatory drugs, underline that AAD and allergy share some pathogenic mechanisms with COVID-19. Besides Treg cells defect, several virus-related mechanisms impair peripheral tolerance, and each mechanism, by itself or in association with others, may contribute to the pathogenesis of AAD-like symptoms. 2.4.1 | Molecular mimicry S1 protein shares sequence homology with an extraordinary number of tissue proteins that, if altered, mutated, deficient, or improperly functioning by cross-reacting Abs, may associate with a wide range of AAD. 67 An epitope mapping analysis has identified linear immunogenic epitopes from DM patients matching with the SARS-CoV-2 peptides. HLA-B*15:03 which associates with Sjogren's Syndrome is able to present highly conserved SARS-CoV-2 peptides. SARS-CoV-2 shares also sequence with proteins of the brainstem respiratory nucleus and with a pulmonary surfactant, possibly explaining neurological and pulmonary damages. 68 The neutrophil extracellular traps (NETs) have been observed in COVID-19 patients with elevated serum levels of cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3. 33, 69 NETs are a way to control microbial infections and this unique cell death program is called "NETosis." NETs can be activated through many disease-related stimuli and mediate tissue damage. Excessive spread of self-antigens, associated with increased NETosis and/or defects of mechanisms for their elimination, leads to AAD and clotting activation. 69 Bystander damage starts when the virus-specific CD8 + T cells are recruited into the infected tissues where they exert cytotoxic activity. Dead cells activate macrophages to release reactive oxygen species and nitric oxide resulting in bystander killing of uninfected cells. 70 CD4+T cells may also contribute to the BD through the release of pro-inflammatory cytokines. 70 Impaired clearance of killed cells induces spreading of autoantigens with the activation of bystander autoreactive T and B cells. BD is responsible for ARDS, myocarditis, and neurological involvement of COVID-19. When the virus persists, it may dysregulate NI in infected cells modifying the environmental signals (mainly IL-1β, but also IL-18 and IL-23) which, in turn, promote: (i) The expression of further proinflammatory molecules; (ii) the amplification of so-called "trained innate immunity;" (iii) the activation of bystander autoreactive T and B cells. All these mechanisms, largely mediated by cytokines of the IL-1 superfamily, contribute to an excessive immune response and to the onset of AAD. 71 The "trained Immunity" leads to an increased response of previously activated innate cells, mostly myeloid and NK cells, to subsequent triggers, defined as "innate immune memory," responsible for the persistence of inflammation in some disorders. 72 "Trained memory" NK cells work as a rapid protective mechanism in secondary infections, but not in SARS-CoV-2 (primary) infection where it would contribute to the increase in the late inflammation. However, some reports indicate that trained innate immunity could overcome also primary infection due to a rapid reaction able to inhibit the virus from further dissemination. 73 Since immuno-senescence is associated with higher memory and lower naive T cells, it has been speculated that such unbalance may contribute to the higher severity of the disease in adults compared with children. 79 In adults, the improved trained immunity is associated with bystander T cell activation, poor clonal T cell expansion, and low viral clearance, while, in children, the predominant naïve T cells develop a valid antiviral response with efficient clonal T cell expansion, viral clearance, and less tissue damage. 77 Besides naïve T cells, children exhibit higher levels of pre-existing cross-reacting IgM+mB cells. 80 Thus, they produce natural antibodies and generate most IgA+ and IgG+ switched mB cells, secreting protective Abs during early infection. 80 Neutralizing IgG from mB cells in children with COVID-19 display none or very few somatic mutations as natural Abs; thus, suggesting that their repertoire share some SARS-CoV-2 specificities. 79 The abundance of naïve T and mB cells in children could contribute to explain why most pediatric patients display no or mild symptoms and early recovery. 81 Table 1 summarizes the topics of the described pathogenic hypotheses, underscoring those to be further thoroughly investigated. No data are available at the present on the proportion of patients in which each mechanism has been recognized: the next proposal to define endo-types relating to variable clinical patterns could fill this gap. Despite the extraordinary amounts of reports, many unknowns on the immune response to the virus and COVID-19 pathogenesis must be further investigated to explain the differences between severe and non-severe COVID-19 and why only a small fraction of patients develop severe symptoms. Although the described hypotheses contribute to shed light on multiple aspects of COVID-19, actually none of them is sufficient to explain the variability of the disease. The current problem is, therefore, to establish the causes of this heterogeneity. Some other viral infections, such as HBV, show variable clinical outcomes owing to different balances between viral load and efficacy of antiviral immune responses. 86 As reported in the graphical abstract, many variable components can contribute to the different outcomes also in SARS-CoV2 infection. The variability F I G U R E 1 Flow chart of immuno-mediated mechanisms leading to symptoms of autoimmune/autoinflammatory diseases in COVID-19 patients of viral load along the disease is of the utmost importance. The virus triggers a lot of co-receptors able to start signals, which, in turn, activate several immunological mechanisms: genetic, epigenetic, pre-existing immunity, polymorphisms of signals/receptors of the immune system, and actually may contribute to the heterogeneity of the final response. Table 2 compares the receptors targeted by S1 protein for their structure, cell, and tissue distribution, and pathophysiology, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] whereas Figure 2 summarizes the pathways of each receptor and the antigenic activity of S1 influencing the immune response. Furthermore, the immune system is diverse in different individuals who rarely respond to an infection in a similar manner. Genetic variations as TLR7 in men, 102 HLA haplotype conditioning adaptive immunity or recognizing cross-reactive autoantigens or SAtgs of S1, molecules involved in IFN signaling, 102 susceptibility to autoimmunity, or to easy NI activation, 54 Factors/mechanisms delaying adaptive immunity. Early alterations in asymptomatic, mild, and severe diseases. The timing and entity of IFN impairment and of NLRP3 inflammasome activation. Macrophages activation and pDC impairment favoring NK dysfunction/exhaustion and trained NK cells response. pDC impairment and reduced antigen presentation to specific T cells. Relationship of delayed adaptive immunity and its relationship with age and other co-morbidity with chronic inflammations. The circulating proportion of memory versus naïve T and B cells in adults compared with children. Endogeneous corticosteroids, TGFβ and IL-10 levels and compensatory hyperactivation of innate immunity and persistence of viral load. Pre-existing immunity to the virus in unexposed individuals 34 Protection given by pre-existing immunity (memory T and B cells) toward SARS-CoV2 infection. The permissive HLA haplotypes favoring a quick secondary-like response. Spectrum of T cell repertoire to CCC epitopes cross-reacting with SARS-CoV−2 ones. The mechanism and timing of memory Treg cells impairment. Levels of Ab-dependent endocytosis in pre-existing immunity. Super-antigenic hypothesis 4 4-46 The SAtgs' sequences of S1 protein. The timing and the degree of SAtg stimulation of T and, subsequently, of B cells. The permissive HLA-haplotypes favoring polyclonal T cell activation till exhaustion. The association with Treg cell impairment and/or superinfection with other pathogens. Unmasking latent autoimmune/ auto-inflammatory mechanisms 39, 40, 42 Mechanism(s) and timing of Treg cells dysfunction. Degree of inflammasome activation of infected cells leading to a prevalent type 3 (Th17, Tc17, ILC3) response. Levels of NET-osis by activated/infected macrophages favoring epitope spreading. Molecular mimicry between SARS-CoV2 epitopes and self-antigens. Fine specificities and pathogenic role of autoantibodies observed in COVID-19. The circulating proportion of memory versus naïve T and B cells in adults compared with children. CD4+/CD8+ T cell ratio and functional Th subsets in different age ranges. Development of Tfh cells, mB cells and humoral response in different age ranges. TCR repertoire and clonal expansion to novel antigens in different age ranges. Impaired cytotoxicity of CD8+ T and NKT cells in elderly favoring not effective response to new viruses. Trained immunity coupled with pro-inflammatory cytokines in the elderly. Abbreviations: CCC, common cold coronaviruses; pDC, plasmacytoid dendritic cells; IFN, interferon; ILC, innate lymphoid cells; NETs, neutrophils extracellular traps; NK, natural killer; SAtgs, superantigens; Th, T helper; Tc, T cytolytic; Tfh, T follicular helper; Treg, T regulatory. Comparative activities of receptors targeted by S1 protein of SARS-CoV2 F I G U R E 2 Multiple functions of SARS-CoV-2 S1 protein. S1 protein interacts with some active receptors/molecules expressed on many cell types, by directly or indirectly interfering with innate and adaptive immune responses. S1 protein induces also HLA-E expression on epithelial cells mediated by GATA3 activation which may negatively affect NKG2A+ NK cells in the lung. S1 protein display also epitopes with superantigenic activity and/or cross-reacting with self-antigens: They may amplify polyclonal activation of not specific T cells or bystander autoreactive T and B cells the produced alterations and damages. Protective endo-types facilitate functional restoration while detrimental ones improve immunological alterations and favor clinical worsening. A list of the major biomarkers associable with protective or detrimental endo-types is reported in Table 4 . [103] [104] [105] [106] [107] [108] [109] [110] The evolving endo-types leading to multiple phenotypes can likely overlap or intersect in a variable way in each patient. An attempt to depict the major evolving endo-types which, through several immune mechanisms, may lead to the major clinical patterns in severe COVID-19 is schematically summarized in Table 5 . in association with essential parameters of inflammation, coagulation, organs' function, etc. (Table 4 ). 135 This approach will allow to establish a detailed guideline to preventively identify immunological alterations correlated to the symptoms trend and to exploit this tool for the most suitable therapeutic strategy in each patient (including mAbs-Sotrovimab, recognizing the virus entry pathways and biologicals targeting pathogenic molecules). Further research based on allergy pathogenesis and its therapeutic approaches is mandatory to better explore COVID-19 heterogeneity. This strategy can also provide an outline of how we may approach emerging infections/ pandemics in the future. This work was supported by grants from the Ministero della Salute Abbreviations: AAD: Auto-inflammatory/autoimmune Disorders; Abs, antibodies; C', complement; MBL, membrane binding proteins; MDSC, Myeloid-derived suppressive cells; ncTh1, not classical Th1 cells; NETs, neutrophil extracellular traps; NK, Natural killer cells; pDC, plasmocitoid Dendritic cells; TF, tissue factor; Tfh, Follicular T helper cells; TLRs, Toll-like receptors; vWF, von Willebrand factor. a Each pathway should not be considered one way, since conditions favoring multiple mechanisms can coexist or intersect each other. Evolving endotypes leading to Phenotypes 1, 2, 5, 6 needs further investigation.and, at presenr, must be considered hypothetical. COVID-19: unanswered questions on immune response and pathogenesis Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8 + T cells Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses Enhanced SARS-CoV-2 neutralization by dimeric IgA SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans The laboratory tests and host immunity of COVID-19 patients with different severity of illness Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Potently neutralizing and protective human antibodies against SARS-CoV-2 Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia Distinguishing between COVID-19 and influenza during the early states by measurement of peripheral blood parameters Cytokines and chemokines in SARS-CoV-2 infections -therapeutic strategies targeting cytokine storm Immunopathogenesis and treatment of cytokine storm in COVID-19 A granulocytic signature identifies COVID-19 and its severity Eosinophils suppress Th1 responses and restrict bacterially-induced gastrointestinal inflammation COVID-19: immune pathogenesis and Immune therapeutics Adaptive immunity to SARS-CoV-2 and COVID-19 Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Comprehensive mapping of immune perturbations associated with severe COVID-19 Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway Novel cooperation between CX3CL1 and CCL26 inducing NK cell chemotaxis via CX3CR1: A possible mechanism for NK cell infiltration of the allergic nasal tissue Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19 HCMV-controlling NKG2C+ NK cells originate from novel circulating inflammatory precursors Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity Longitudinal analyses reveal immunological misfiring in severe COVID-19 Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity Sinai Immunology Review Immunology of COVID-19: current state of the science Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 Human germinal centres engage memory and naive B cells after influenza vaccination The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome-the superantigen hypothesis Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation Identification of a unique TCR repertoire, consistent with a superantigen selection process in Children with Multi-system Inflammatory Syndrome Autoimmunity as the comet tail pf COVID-19 pandemic Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 Anti-Phospholipid Antibodies in COVID-19 Are Different from Those Detectable in the Anti-Phospholipid Syndrome Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Diverse Functional Autoantibodies in Patients with COVID-19 Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomized controlled trial Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2 Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice Could Histamine receptor antagonists be used for treating COVID-19? Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19 Identification of antiviral antihistamines for COVID-19 repurposing Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases On the molecular determinants of the SARS-CoV-2 attack Neutrophil extracellular traps in COVID-19 Pathogenic function of bystanderactivated memory-like CD4(+) T cells in autoimmune encephalomyelitis Do inflammasome impact COVID-19 severity? Virusdisease Trained immunity: an ancient way of remembering Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guerin vaccine: mechanisms, challenges and perspectives T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies Adult-onset Still's disease SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself Immunosenescence and inflammatory aging as two sides of the same coin: friends or foes? Front Immunol Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Warriors of SARS-CoV-2 Infection Lack of Gut Secretory Immunoglobulin A in Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019 Severity of illness scores at presentation predict ICU admission and mortality in COVID-19 Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 COVID Processing Unit Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection Cell entry mechanisms of SARS-CoV-2 Receptor recognition mechanisms of coronaviruses: a decade of structural studies SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor T-Cell hyperactivation and paralysis in severe COVID-19 infection revealed by single-cell analysis Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease Ratio of CD147 high /CD147 low in CD4 + CD25 + T cells: A potential biomarker for early diagnosis and prediction of response to therapy for autoimmune diseases CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells Cell Adhesion Molecules Turned to Pathogen Recognition Receptors DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes Interaction between non-coding RNAs and Toll-like receptors Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs Protein-glycan interactions in the control of innate and adaptive immune responses Genetic mechanisms of critical illness in COVID-19 Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia Cytokine signatures of end organ injury in COVID-19 Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity Chemokines and chemokine receptors during COVID-19 infection The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease B cell memory: understanding COVID-19 Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics Cardio-pulmonary-renal consequences of severe COVID-19 The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute Respiratory Distress Syndrome Description and Analysis of Cytokine Storm in Registered COVID-19 Multisystem inflammatory syndrome in children: unique disease or part of the kawasaki disease spectrum? Front Pediatr Haemophagocytic syndrome and COVID-19 Sepsis Subclasses: A Framework for Development and Interpretation Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in coronavirus disease 2019 Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019 Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study Role of the Immune Microenvironment in SARS-CoV-2 Infection COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome Association between cytokine profiles and lung injury in COVID-19 pneumonia Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection Different endotypes and phenotypes drive the heterogeneity in severe asthma Phenotypes and endotypes of food allergy: A path to better understanding the pathogenesis and prognosis of food allergy Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort Atopic dermatitis endotypes and implications for targeted therapeutics Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis Mechanisms of asthma and implications for its prevention and treatment: a personal journey Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4 Biological treatments for severe asthma Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19 The authors declare that they have no conflicts of interest.